News
Onco Sil joins PALACROS to test repeat intratumoural therapy in pancreatic cancer
17+ hour, 30+ min ago (242+ words) Onco Sil Medical (ASX: OSL) has been chosen to join PALACROS, a major European academic consortium aimed at improving outcomes for patients with unresectable locally advanced pancreatic cancer By participating through its European arm, Onco Sil Medical Europe Gmb H,…...
Regenerative breast scaffolds point to a new era in reconstructive surgery
16+ hour, 15+ min ago (320+ words) Thirty Australian women have already experienced restorative breast surgery using absorbable scaffolds designed to regenerate lost breast tissue, and the company behind the technology is moving quickly through human trials. Bella Seno has completed a world-first safety study and is…...
BCAL takes stake in Genetic Signatures to broaden diagnostics capabilities
17+ hour, 5+ min ago (258+ words) BCAL Diagnostics (ASX: BDX) has taken a strategic minority stake in fellow ASX-listed company Genetic Signatures by acquiring 23, 173, 644 shares, representing 10. 2 per cent of the business, for cash consideration of $1. 4 at 6 cents per share. The deal gives BCAL exposure to an…...
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
18+ hour, 5+ min ago (227+ words) Cartherics has been recognised as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell and Gene Therapy Excellence Awards 2026, a milestone that highlights the company's rise in the off-the-shelf immune cell therapy field. Based in Melbourne, the…...
Starpharma advances DEP HER2 Lu toward first in human study after strong preclinical data
18+ hour ago (343+ words) Starpharma (ASX: SPL) has reported encouraging preclinical results for its DEP HER2 targeted radiotherapy candidate, DEP HER2 Lu, that pave the way for a planned first-in-human Phase 1 study in the second half of 2026. The company says the construct combined a HER2-targeting nanobody,…...
Algorae named launch partner for healthcare in new Sovereign AI Infrastructure initiative
2+ day, 17+ hour ago (285+ words) Algorae Pharmaceuticals (ASX: 1 AI) has been announced as a foundation participant and the healthcare and life sciences launch partner for the Sovereign AI Infrastructure initiative, led by Agentic Scale. ai and built on NVIDIA-accelerated technology. The initiative is being positioned…...
Disappointment for CSL as Europe recommends reversing approval of therapy - Biotech
2+ day, 17+ hour ago (268+ words) CSL has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use issued an opinion recommending the revocation of the EU marketing authorisation for TAVNEOS (avacopan) following a review under Article 20 of the handling of data in…...
INOVIQ CAR exosomes show rapid tumour killing in ovarian cancer models
1+ week, 17+ hour ago (394+ words) Biotech Dispatch INOVIQ CAR exosomes show rapid tumour killing in ovarian cancer models INOVIQ (ASX: IIQ) has reported positive in vitro proof-of-concept data demonstrating that its CAR exosome platform can rapidly kill ovarian cancer cells. The study evaluated CA125- and EGFR-targeting…...
Nyrada advances trial with new sites and plan to accelerate recruitment
2+ week, 2+ day ago (240+ words) Nyrada (ASX: NYR) says its PROTECT MI Phase 2a study of Xolatryp remains on track for completion in calendar 2027 and is moving through the staged rollout typical of first-in-patient cardiovascular studies. To capture those missed patients and accelerate recruitment, Nyrada said…...
Memphasys wins exclusive national supply deal with Monash IVF for Felix system
2+ week, 2+ day ago (206+ words) Memphasys (ASX: MEM) has announced a 12-month exclusive national supply agreement with Monash IVF Group for the Felix automated sperm selection system. The agreement follows more than a decade of collaboration between the companies and the completion of a pivotal…...